ArticleJournal of musculoskeletal & neuronal interactions2018
Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice.
Article in Journal of musculoskeletal & neuronal interactions, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- Effect of bisphosphonate on temporomandibular joint in osteopenia-induced rats by botulinum toxin A injection on masticatory muscle: a preliminary study.Maxillofacial plastic and reconstructive surgery · 2019Article
- Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDisuse is characterized by a rapid and profound bone resorption. Zoledronic acid (Zol) inhibits osteoclastic bone resorption. The aim of the study was to prevent disuse osteopenia with Zol and investigate gene expression markers of osteoclastic differentiation.
methodsDisuse osteopenia was induced by injecting botulinum toxin (BTX) into the right hind limb of 16-week-old C57BL/6J female mice. Zol (100 µg/kg) was injected s.c. once at study start. The immobilized bones were investigated with DEXA, microCT, mechanical testing, dynamic bone histomorphometry, and RT-qPCR.
resultsThe BTX-injections resulted in a loss of cortical and trabecular bone as well as mechanical strength compared to intact baseline and control mice. Treatment with Zol prevented the loss of bone and mechanical strength. Interestingly, treatment with Zol resulted in a higher expression of Nfatc1 and Dcstamp, which are markers osteoclastic differentiation.
conclusionsZol effectively prevented BTX-induced disuse osteopenia. Furthermore, gene expression markers of osteoclastic differentiation were increased in Zol treated immobilized mice, indicating that Zol only affect mature bone resorbing osteoclasts in vivo. However, the current findings are preliminary and calls for further studies.
Indexed as
Identifiers
29855438PMC6016491W2989456919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.